Share this:

Ependymoma Advancements

Ependymoma Meeting Attendees

Ependymoma Consensus Meeting 

The Fourth Biennial Ependymoma Consensus was held at NIH, February 20 to 22, 2019. Neuro-oncology experts worldwide met to advance their knowledge and collaborate to find better treatments for people with ependymoma.

In its history, the Ependymoma Consensus has helped define areas of research for ependymoma and advance therapies for patients. Importantly, the consensus is an international collaboration. Participants recognize the complexity of ependymoma – a rare brain and spine cancer – and the need to work together to understand tumor genetics and molecular characteristics to advance treatments.

During the 2019 consensus, participants presented the latest research and advances in the field. Then, they gathered in three working groups to discuss preclinical models, the pathology and molecular classification of tumors, and to discuss clinical trial designs.  


CERN Advisor Reports on Clinical Trials and Advances in Care 

CERN Advisor Mark Gilbert, M.D., presented the final report of the CERN 08-02 study at the Society for Neuro-Oncology Annual Scientific Meeting. The phase II study of dose-dense temozolomide and lapatinib is the first prospective clinical trial in adult patients with ependymoma.

“The results are very dramatic,” Dr. Gilbert said. The report showed that the drug combination had objective responses and prolonged progression-free survival. For patients with spine tumors, improvements in performance status, disease-related symptoms and symptom interference was seen. For patients with brain tumors, improvements in performance status and stability of most disease-related symptoms was reported.


Attend the Ependymoma Awareness Butterfly Release

The CERN Foundation will commemorate Ependymoma Awareness Day with a mass butterfly release that will take place on May 5 during the 2019 National Brain Tumor Soceity's Head to the Hill activities in Washington, DC.
If you would like to attend the butterfly release, please RSVP to
Kimberly Wallgren

Ependymoma Foundation Informs and Inspires a Rare Cancer Community 

Kimberly Wallgren shares how her father’s cancer inspired a non-profit to educate and connect people living with ependymoma.

In March 2007, the CERN Foundation held its first meeting. Clinicians, researchers, and family of ependymoma survivor, Dallas Mathile, gathered to discuss how they could impact the lives of people with ependymoma.
This effort was led by neuro-oncologist Mark Gilbert, M.D., now chief of NCI’s Center for Cancer Research (CCR), Neuro-Oncology Branch, who asked other experts willing to collaborate to join him. These leaders continue to be CERN advisors today. 
Follow us.
Friend us.
Follow us.
CERN Foundation PO Box 217 | Zionsville, IN 46077 US
powered by emma
Subscribe to our email list.